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 Normal physiology 
The islets of Langerhans are regions of the human pancreas that contain endocrine (hormone-
producing) cells, constituting 1 to 2% of pancreas volume. There are four main types of 
endocrine cells within the islets of Langerhans; alpha (α) cells, beta (β) cells, delta (δ) cells and 
to a lesser degree the pancreatic polypeptide (PP) cells. Of these populations, the β-cells 
account for between 65-80% of the pancreatic islets, and whilst predominately responsible for 
the secretion of the hormone insulin, they also co-secrete C-peptide and amylin. Collectively, 
the cells in the islets of Langerhans are pivotal in glycaemic regulation and homeostasis.  
The determinant of plasma glucose concentration is a function of the rate at which glucose 
enters the circulation (glucose appearance), balanced by the rate at which glucose is removed 
(glucose disappearance) 1. Circulating glucose originates from three sources; post-prandial 
intestinal absorption, glycogenolysis and gluconeogenesis. The attainment of glucose 
homeostasis requires a continuous interplay between several glucoregulatory hormones split 
via their ability to increase (glucagon, adrenaline, cortisol, growth hormone) or decrease 
(insulin) plasma glucose concentrations.  
In regulatory metabolism, insulin is endogenously released in two phases. The first phase 
release occurs acutely and rapidly (~10minutes) in response to elevated circulating glucose 
levels. The second phase is independent of circulating glucose concentrations and occurs in a 
continuous, gradual release from the newly formed vesicles 2. Elevations in blood glucose 
increase the rate of insulin secretion from the β-cells. Once bound to its cell surface receptor, 
insulin facilitates the entry of extracellular glucose into the intracellular space, thereby 
lowering circulating levels of blood glucose. However, when glucose levels drop beyond those 
accepted within physiological norms i.e between 4-7mmol/L-1, insulin release slows or 
completely stops to avoid hypoglycaemia. A drop beyond this point (≤3.6-3.9mmol/L-1) 
typically triggers the activation of several gluco-regulatory hormones i.e. glucagon and 
adrenaline which promote hepatic mediated glucose production via the process of 
glycogenolysis. 3 4.  
Type 1 diabetes 
Type 1 diabetes mellitus (T1D) is an autoimmune disease characterised by the progressive 
depletion and destruction of pancreatic β-cells, which results in hyperglycaemia and a 
propensity to develop diabetic ketoacidosis (DKA). However, whilst primarily associated with 
defective insulin secretory capacity, β-cell death also contributes to a progressive loss in α-cell 
function 5. As a result, there is often a compromised functionality of glucagon, a peptide 
hormone which operates to raise glucose concentrations in response to low levels of circulating 
insulin. An impairment in these processes leads to an increased reliance on the third counter-
regulatory mechanism i.e the release of adrenaline. As such attenuation or loss of this response 
can lead to hypoglycaemia unawareness, a condition which can have serious and sometimes 
fatal consequences 6. 
Exogenous Insulin Therapy  
Clinically, the inability of those with T1D to produce insulin necessitates a lifelong reliance on 
exogenous insulin therapy, typically administered by subcutaneous (SC) injection. Slight 
variations of the human insulin molecule are referred to insulin analogues. The term reflects 
the fact that they are not technically human insulin, rather they are analogues which retain the 
hormone’s glucose management functionality.  
When insulin is used in a clinical setting, a volume is injected into a site of subcutaneous tissue. 
The majority of existing insulin analogues are injected in hexameric form, however, hexamers 
are too large to readily pass through capillary fenestrae, and thus must first disassociate into 
either dimers or monomers within the injection depot before entering the circulation. In primary 
target tissues, the exogenously administered insulin molecules bind to and activate insulin 
receptors, thereby triggering cellular cascades that promote intracellular glucose uptake and 
utilisation.  
The pharmacological production of insulin has progressed substantially since its discovery in 
1921, with significant biochemical adjustments having been made to improve both 
pharmacokinetic and pharmacodynamic profiles. The progression from purified animal to 
recombinant human insulin was made by Eli Lilly, who produced insulin Humulin in 1982. 
Since then, the variety of insulin analogues has expanded considerably, encompassing a range 
of products that differ in their duration of action, time of onset and peak effect. The type of 
insulin analogue largely reflects its absorption rate, thus insulins are classified in relation to 
their duration of action i.e ultra-fast acting, fast-acting, short-acting, intermediate-acting, long-
acting, ultra-long acting, and combination products (Table 1).  
 
Table 1. Synopsis of currently available insulin analogues for individuals with type 1 diabetes  
 
Insulin Type Insulin Name 
Pharmaceutical 
Manufacturer 
Duration of Action 
Reference 
Duration Onset Peak 
ULTRA-FAST ACTING  FIasp Novo-Nordisk 3-5 hours  3-5minutes  45-60min 7 
FAST  
Humalog 
(lispro) 
Lilly 
3-5 
hours 
5-20 
min 
45-60 
min 
8 
Apidra 
(Glulisine) 
Sanofi Aventis 
3-5 
hours 
10 
min 
45-60 
min 
9 
Novorapid (Aspart) Novo-Nordisk 
3-5 
hours 
10 
min 
45-60 
min 
10 
SHORT 
Humulin R Lilly 
6-8 
hours 
0.5-1 
hours 
2-4 
hours 11 
Actrapid Novo-Nordisk 
8 
hours 
0.5 
hours 
2.5-5 
hours 
INTERMEDIATE 
Humulin N Lilly 
18-24 
hours 
1-2 
hours 
6-12 
hours 12 
Novo NPH Novo-Nordisk 
24 
hours 
1.5 
hours 
4-12 
hours 
Humulin L Lilly 
18-24 
hours 
1-3 
hours 
6-12 
hours 
Diabetes Care 
Programme of Nova 
Scotia (2002) 
Novolin Lente Novo-Nordisk 
22 
hours 
2.5 
hours 
7-15 
hours 
COMBINATION  
Humalog Mix (25% Lispo & 75% protamine 
suspension) 
Lilly 
18-24 
hours 
30-45 
min 
0.75-2.5 
hours 
Humulin 20/80 Humulin 30/70  Lilly 
18-24 
hours 
30 
min 
2-12 
hours 
LONG 
Humulin U Lilly 
24-28 
hours 
4-6 
hours 
8-20 
hours 12 
Novolin Ultralente Novo-Nordisk 
28 
hours 
4 
hours 
8-24 
hours  
Lantus (Glargine) Lantus 
20-24 
hours 
1.5 
hours 
None 12 
Levemir (Detemir) Novo-Nordisk 
20-24 
hours 
2.5 
hours 
None 13 
ULTRA LONG 
Degludec (Tresiba) Novo-Nordisk 
42 
hours 
30-90 
min 
None 14 
U300 Glargine  Toujeo 
>30 
hours 
30-90min None 15 
Developments in Basal insulin analogues  
In the case of basal insulin development, the challenge has been to retard absorption to a greater 
extent than occurs with human insulin – ideally to produce a constant, peak-less kinetic profile 
that more mimics normal basal insulin secretion 16.  
Unlike endogenous insulin production (which is secreted in a glucose-dependent manner), the 
dose of exogenous insulin must be manually titrated to maintain euglycemia 17. As such, 
correctly identifying a dosing strategy across a 24hour time span is an important feature for 
minimising within-patient variability 17. However, basal analogues have presented a number of 
flaws which compromise the attainment of this goal. Produced back in the 1950’s, the original 
human insulin-based products, such as NPH insulin, had suboptimal pharmacokinetic (PK) 
profiles, characterised by inappropriate peaks of action coupled with high variability from 
injection to injection. Combined, these attributes not only accentuated the risk of 
hypoglycaemia but also necessitated the need for twice daily dosing.  
In the early 2000’s, insulins detemir (TM Levemir) and glargine (TM Lantus) were created in 
an attempt to overcome some of the PK issues of their preceding analogues.  
However, in comparison to regular human insulin, neither provide an ideal absorption profile 
that closely mimics normal physiology 16. Thus, the development of ultra-long acting insulins 
that achieves steady state PK with a low peak: trough ratio should be of clinical and patient 
advantage.  
 
Insulin Glargine 300units/mL 
Insulin Glargine (IGlar) substitutes the amino group 21A-Asn for Gly thereby forming its 
unique chemical structure (21A-Gly-31B-Arg-32B-Arg-human insulin)15. Following 
subcutaneous injection, IGLar precipitates at physiological pH to form a depot from which 
insulin glargine is slowly released 18. In 2015, a more concentrated form of IGlar [insulin 
glargine 300 units/mL (IGlar U300)] was released. IGlar U300 has a reduced redissolution rate, 
longer duration of action and lower fluctuation rate following subcutaneous injection compared 
to glargine 100 units/mL (U100) 19. However, whilst its PK and pharmacodynamic profile is 
improved, ultrastructural three-dimensional research has observed the formation of larger 
microprecipitates in the tissues following IGLar U300 injection. Physiologically, this may 
cause a disproportionate release and delayed absorption rate of insulin into the blood stream 
(Seested et al, 2016) 20 
Insulin Degludec  
Recently, the development of insulin Degludec (IDeg); a new ultra-long acting insulin analogue 
with a duration of action that comfortably exceeds 24hours, has been achieved 17. The name 
‘’De-gluc-dec’’ originates from its unique structural profile which acylates DesB30 at the ε-
amino group of LysB29 with a glutamic acid ligand at position 29. The opposing end of this 
glutamic acid ‘spacer’ is then attached to a hexadecandioyl 16 fatty diacid side chain, 
completing the biochemical structure of IDeg. 
Pharmacological profile 
The impressive pharmacological profile of IDeg derives from its specifically engineered 
molecular structure which encourages mutli-hexamer formation via a prolonged depot 
release17. To date, IDeg is the only insulin analogue to self-associate into multi-hexamers upon 
SC injection. In the pharmaceutical formulation i.e in the presence of phenyl and zinc, the IDeg 
hexamers adopt a formation from which only one hexameric end can interact with the side 
chain of another 17. After injection, the phenol is lost and the dihexamer poles open at both 
ends thereby enabling the formation of long soluble multihexamer chains 21. The loss of zinc 
allows the monomers to be slowly released which adeptly creates a soluble depot from which 
IDeg is gradually absorbed into the circulation on a continuous basis. 
Pharmacokinetic profile  
The ultra-long profile of IDeg brings with it several clinically relevant glycaemic outcomes. 
Firstly, research has shown that steady state (SS) concentrations of IDeg are reached within 3 
days of once-daily dosing with no risk of insulin ‘stacking’22. Moreover, concentration-time 
curves and glucose infusion rate (GIR) profiles obtained during a one-dosing interval at SS 
conditions have highlighted the consistent distribution of IDeg formulations over a typical 24 
hr treatment interval 23.  
The flat shape of the pharmacodynamic profile of IDeg is supported by parameters such as 
distribution of the glucose lowering effect and relative fluctuation17 Importantly, these 
characteristics support a glucose lowering effect across a range of clinically relevant dose levels 
(0.4, 0.6 or 0.8 u/kg)24. Moreover, recent comparative research investigating glycaemic 
outcomes associated with IDeg versus IGLar U300, found IDeg produced a lower day-to-day 
and within-day variability than that of IGlar U300 in patients with T1D. 20 Finally, the peak-
less, extended and highly predictable glucose lowering profile of IDeg allows for variation in 
the once-daily-dosing strategy of up to 8 hours 25 26 which has important social and practical 
patient appeals 27.  
Clinical questions and concerns 
The new generation of ultra-long basal insulins provide improved therapeutic care for patients 
with T1D. However, although progressive, the introduction of any new product demands 
careful consideration of important clinical outcomes. Similar to that of its preceding analogues, 
the efficacy of IDeg in minimising the occurrence and magnitude of hypoglycaemic requires 
thorough investigation. Unsurprisingly, both iatrogenic and exercise induced hypoglycaemia 
represent major concerns in this patient population. Thus, considering the heightened risk of 
developing hypoglycaemia both during and as long as 24 hours after exercise participation, 28 
29 insulin management must be carefully considered.  
During exercise, the increased skeletal muscle contraction rates, heightened insulin sensitivity 
and inability to regulate circulating insulin concentration result in an augmented skeletal 
muscle uptake but decreased appearance of circulating blood glucose. These physiological 
responses, coupled with the more rapid appearance of exogenous insulin due to elevations in 
both thermo-and-hemodynamics as well as an inability to effectively counteract the drop-in 
glucose concentrations, exacerbate the likelihood of hypoglycaemia in individuals with T1D.   
Therefore, although the importance of regular physical exercise in glucose management for 
individuals with T1D is magnified by its acknowledgement as a key adjunct to insulin therapy 
by several governmental, charitable and healthcare organisations - exercise participation rates 
remain low, with fears around loss of glycaemic control during and after exercise reported as 
one of the major barriers to regular engagement 30.  
These fears are perhaps exacerbated by uncertainty in how to appropriately adjust exogenous 
insulins around exercise to best preserve blood glucose concentrations.  
Whilst research has highlighted improved post exercise glycaemia when bolus insulin is 
reduced in the pre-and-post-exercise period 31, adjustments have mostly been done against a 
background of the basal insulins IGlar, NPH or IDet 32 33, 34, 35, 36, 37, 38 39 with less work 
investigating IDeg.  
 
For the majority of patients, basal insulins are not normally adjusted in anticipation of exercise. 
However, complete suspension of basal insulin administration in pump users during exercise 
has been found to decrease exercise-induced hypoglycaemia by ~30% in children and 
adolescents 40. Although an effective strategy for pump users, complete basal omission in those 
using multiple daily injections (MDIs) is difficult and potentially dangerous. Encouragingly, 
recent work reported complete protection from exercise-induced and nocturnal episodes of 
hypoglycaemia when patients on MDI reduced basal insulin IGLar and IDet by 20% the 
morning of an anticipated exercise session in combination with a 75% reduction in rapid-acting 
insulin (100% dose =9, 80% dose = 0) 41.  
Whilst still in its infancy, research has started to explore glycaemic outcomes associated with 
exercise and/or bolus insulin manipulations on a background of IDeg in patients with T1D. 
Initial work by Moser and colleagues reported no hypoglycaemic episodes both during and 
after high intensity interval-and-continuous-exercise when multiple adjustments in bolus 
insulin were made on a background of stable IDeg dosing 42. More recently, comparative work 
has highlighted the low and similar risk of exercise-induced hypoglycaemia on a background 
of IDeg and IGlar. 43. However, whilst IDeg has been used as the basal insulin, these studies 
have only involved acute manipulations to pre-exercise bolus insulin with no basal adjustments 
being made. Addressing this gap, Moser et al. was the first to experiment with IDeg 
adjustments around exercise in individuals with T1D 44.  
Description of Othmar paper 
Nine T1D individuals on a background of IDeg were recruited into the study. The authors set 
out to assess the effects of a reduction in IDeg around multiple aerobic exercise sessions at a 
moderate intensity (63 ± 7% VO2 max). Basal insulin dose reductions were introduced 3 days 
before the first exercise session, with 5 consecutive days of exercise being performed under 
either a 100% or 75% individualised IDeg dose. Trials were separated by a four-week wash 
out period and acutely standardised with participants consuming a comparable ~63g CHO at 
least two hours before the start of exercise combined with an individualised bolus insulin dose. 
This minimised the possible contributions of opposing basal and acute bolus insulin 
manipulations on exercise performance and glycaemia. 
The two main variables assessed were (1) time spent in specific glycaemic ranges and (2) 
number of hypoglycaemic events over the five days of consecutive exercise. The study 
concluded that a 25% reduction of basal IDeg around exercise has the potential to increase time 
spent in euglycaemia, though had no influence on time spent in hyper- or hypoglycaemia or 
the number of hypoglycaemic episodes. 
Critique 
This study provided an excellent insight into acute glycaemic outcomes associated with IDeg 
manipulations around exercise. However, subject numbers were small and included a relatively 
homogenous group with good glycaemic control. This not only makes wider generalisation 
difficult, but also overlooks important diabetes related variables. Moreover, the dose reduction 
was made three days prior to the initial exercise session. Outside of elite or specifically 
structure sports programming, this degree of forewarning is largely unrealistic for the majority 
of recreationally active individuals. Thus, given the ultra-long duration of IDeg, questions 
remain as to whether a reduction in the basal insulin dose on the day of, or evening before the 
anticipated exercise provides protection against the risk of hypoglycaemia. 
Finally, although overall time spent in glycaemic ranges provides valuable metrics, a further 
breakdown focusing on specific time frames i.e acutely post exercise and nocturnal periods, 
would be of much clinical and practical relevance. 
Further research going forward 
With new insulin analogues that differ in their pharmacokinetic and pharmacodynamic profile 
being made available, exploring the interaction of modern insulin analogues and exercise is 
crucial in our understanding of how we can encourage patients with type 1 diabetes to maintain 
a physically active lifestyle. The results of this study have set a premise for future research 
which should continue to investigate the effect of IDeg manipulations around exercise, 
carbohydrate feeding and rapid acting insulin adjustments. From a clinical perspective the 
inclusion of patients with varying degrees of glycaemic control and physical fitness would 
provide invaluable information that assists the development of exercise guidelines.  
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